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Abstract: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteolytic enzymes that degrade extracel-
lular matrix (ECM) components like collagen, fi bronectin, and laminin. While this activity is important for normal develop-
ment, morphogenesis, and wound healing, deregulation of MMP activity has been implicated in a number of cardiovascular 
diseases, including congenital heart defects, atherosclerosis, myocardial infarction, and congestive heart failure. MMPs are 
good potential diagnostic indicators of cardiovascular disease, but current detection methods are time consuming and quite 
laborious. This review will discuss MMP biology, current methods for detection of MMPs from patient samples, and poten-
tial new developments in multiplexed analysis of MMPs.
Keywords: matrix metalloproteinases, MMPs, analytical methods, cardiovascular disease
MMP Biology
Extracellular enzymes play a crucial role in the interaction between cells and their environment. Matrix 
metalloproteinases (MMPs) are a family of zinc-dependent proteolytic enzymes important in the deg-
radation and turnover of extracellular matrix (ECM) components like collagen (Visse and Nagase, 
2003). Since the initial description of collagenolytic activity in tadpole tail resorption (Gross and Lapiere, 
1962), MMPs have been shown to function in tissue remodeling, embryonic development, morphogen-
esis, reproduction, cell-cell adhesion, migration and invasion, and growth factor and cytokine signaling 
(Nagase and Woessner, 1999). There are fi ve major types of MMPs that were initially categorized 
according to substrates, including collagenases, gelatinases, stromelysins, matrilysins, and membrane-
type MMPs (Folgueras et al. 2004). It is now known that many MMPs have multiple substrates, and 
the current nomenclature uses a numerical system in which these enzymes are classifi ed by domain 
structure rather than by substrate. To date, twenty-four different MMPs have been identifi ed, based 
largely on sequence homology with collagenase-1 (MMP-1). Table 1 contains a list of MMPs, includ-
ing the current name, the old substrate-based name, information about the molecular features of the 
enzyme, and possible roles in human physiology for each enzyme. Figure 1 shows a schematic diagram 
of the MMP structure showing the arrangement of the various domains.
Each MMP consists of a specifi c domain sequence which includes the signal peptide, the pro-peptide 
domain, the catalytic domain, and the C-terminal hemopexin-like domain, which is present in almost 
all MMPs. Several MMPs (e.g. MMP-14, -15, -16, and -24) have additional domains such as a trans-
membrane and a cytoplasmic tail (Nagase and Woessner, 1999). MMPs are typically found in an 
inactive pro-enzyme form known as a zymogen, and cleavage of the pro-peptide domain yields the 
active proteinase. The pro-peptide domain is part of a cysteine switch motif that contains the conserved 
amino acid sequence PRCGXPD; this maintains the enzyme in an inactive form by interacting with 
the zinc ion at the active site and preventing binding of the substrate (Van Wart and Birkedal-Hansen, 
1990; Becker et al. 1995). The catalytic domain contains the catalytic zinc ion bound by three histidine 
residues in conserved sequence HEXGHXXGXXH. X-ray crystallography and nuclear magnetic 
resonance have determined the three-dimensional structure of the catalytic domain to contain a fi ve-
stranded β-pleated sheet, three α-helices, and connective loops (Visse and Nagase, 2003). In addition 
to the catalytic zinc ion, the catalytic domain generally contains one structural zinc ion and one or 
more calcium ions (Bode et al. 1999). The catalytic domain is connected to the hemopexin-like domain 
by a fl exible hinge region that is variable in length. The hemopexin-like domain is located at the 
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C-terminus of the protein. This region is named 
for its structural similarities to the serum glyco-
protein hemopexin, which binds to heme groups 
and helps prevent oxidative stress. The hemopexin 
domain found in MMPs has a four-bladed β-
propeller fold containing a stabilizing disulfi de 
linkage between blades I and IV (Cha et al. 2002). 
These domains typically mediate protein-protein 
interactions and are likely to contribute to substrate 
specifi city for each MMP (Overall, 2002).
MMPs are generally secreted as pro-enzymes 
requiring cleavage in order to be activated. In vivo, 
activation commonly occurs through interaction 
with plasmin or via interaction with other protein-
ases (Lijnen, 2001). MMP activity can also be 
controlled by a series of endogenous inhibitors, 
including α2-macroglobulin in the plasma (Cawston 
and Mercer, 1986) and TIMPs (tissue inhibitors of 
metalloproteinases) in the tissues. Four TIMPs are 
currently known to form complexes with MMPs 
and inhibit enzyme activity (Visse and Nagase, 
2003). The overall ratio of TIMPs levels to MMPs 
levels are thought to be a major determinant of 
MMP activity. TIMPs generally consist of an 
N-terminal domain and smaller C-terminal domain 
connected by a ridge-like loop structure (Fig. 1B). 
Both the N-terminal and C-terminal domains 
contain several disulfi de bridges, and the entire 
molecule forms a wedge structure that inserts into 
the active site of the MMP, inhibiting enzyme activ-
ity. In addition, MMP activity may be inhibited by 
several other molecules, including the NC1 domain 
of type IV collagen (Petitclerc et al. 2000), tissue 
factor pathway inhibitor-2 (Herman et al. 2001), 
and RECK (reversion-inducing cysteine-rich 
protein with kazal motifs) (Oh et al. 2001; Liu et al. 
2003). The extensive and complex regulation of 
MMPs highlights their important role in normal 
human physiology.
Deregulation of MMPs has been implicated in 
a wide variety of human diseases, most notably in 
tumor progression and metastasis for several forms 
of cancer, particularly breast (Duffy et al. 2000; 
Yoon et al. 2003; Folgueras et al. 2004; Stuelten 
et al. 2005; Jinga et al. 2006), ovarian (Kim et al. 
2006), and gastric carcinomas (Torii et al. 1997) . 
Other pathologies associated with inappropriate 
MMP activity include rheumatoid arthritis (Maeda 
et al. 1995; Brennan et al. 1997; Yamanaka et al. 
2000), hepatitis (Lichtinghagen et al. 2000; 
Koulentaki et al. 2002), and osteoarthritis of the 
hip (Masuhara et al. 2002). In addition, MMPs 
have been recognized as having signifi cant roles 
in the development of a wide range of cardiovascular 
N-terminal domain 
C-terminal domain 
Reactive ridge 
A
B
Zn2+
Signal
sequence
Propeptide
PRCGXVPD  
Catalytic domain Hinge region 
Homopexin domain 
Figure 1. Schematic diagram of MMP domain structure (A). TIMP domain structure (B).
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diseases, including congenital heart defects 
(Brauer, 2006), atherosclerosis (Galis et al. 1994; 
Kalela et al. 2002; Watanabe and Ikeda, 2004), and 
myocardial infarction (Kai et al. 1998; Zhao et al. 
2005). The concentrations of MMPs found in 
patient samples in some of these diseases are 
shown in Table 2. Whether MMPs can be used as 
reliable indicators of disease state or not remains 
to be seen and will likely depend on advances in 
analytical detection methods.
MMPs in Cardiovascular Disease
Each year more than 25,000 babies in the United 
States are born in with congenital heart defects. 
During embryogenesis, the formation of the 
heart and vasculature requires extensive cell 
migration, proliferation, and organization into 
three-dimensional networks, and MMPs are key 
regulators of these processes. MMP-2 is one of the 
earliest MMPs known to be expressed during heart 
development (Cai et al. 2000). Neutralizing anti-
bodies for MMP-2 or the use of broad spectrum 
MMP inhibitors led to severe heart tube defects in 
avian embryos (Linask et al. 2005). Midline fusion 
was prevented and cardiac bifi da occurred because 
the MMP-2 inhibition, suggesting a crucial role 
for this enzyme in normal cardiac development. 
Additional studies are required to understand the 
extent of MMP involvement in embryonic cardio-
vascular development and the degree to which they 
contribute to congenital defects.
A growing body of evidence indicates that 
increased MMP activity plays a role in the 
development of adult cardiovascular disease. 
Atherosclerosis occurs when injury to the endothelial 
lining leads to accumulation of lipids and infi ltration 
of activated monocytes, leading to formation of a 
plaque. MMP activity, mainly from activated 
vascular macrophages, may contribute to either 
plaque formation or the rupturing of plaques leading 
to coronary occlusion, or both (Watanabe and Ikeda, 
2004). Atherosclerotic plaques were found contain 
signifi cantly higher quantities of activated MMP-2 
than non-atherosclerotic tissue extracts (Galis et al. 
1994), and subjects with acute coronary syndrome 
have increased plasma levels of MMP-1, -2, and -9 
(Palazzuoli et al. 2006). MMP-8 concentrations were 
reported to be higher in patients with coronary artery 
disease (CAD) compared to those without CAD, and 
MMP-8 levels were also increased with the number 
of stenotic vessels (Kai et al. 1998). Another study 
involving patients with coronary atherosclerosis 
indicated similar fi ndings for MMP-9 (Kalela et al. 
2002); serum concentrations were highest in patients 
with 3-vessel CAD (see Table 2 for 1- and 2-vessel 
CAD), and the difference remained statistically 
signifi cant after adjustment for age, diabetes, and sex 
(p = 0.025). MMP-9 was reported to be a novel 
predictor of CAD mortality based on a study 
involving 1127 patients with documented CAD 
(Blankenberg et al. 2003); the results showed that 
97 patients who died from cardiovascular causes had 
a median concentration of serum MMP-9 of 62.2 
ng/mL as compared to 47.8 ng/mL for those who did 
not have a fatal cardiovascular event (p = 0.0001). 
MMP-9 and TIMP-1 concentrations were found to 
decrease and increase, respectively, across the 
coronary sinus (Inokubo et al. 2001).
In in-vivo studies using apolipoprotein 
E-defi cient mice, over-expression of activated 
MMP-9 by tissue macrophages enhanced the inci-
dence of plaque rupture (Gough et al. 2006). In 
direct contrast, increased plaque rupturing was 
observed in apoE/MMP-9 double knockout mice, 
suggesting that MMP-9 might normally play a 
protective role in plaque stabilization (Johnson 
et al. 2005). The same study demonstrated that 
MMP-12 might contribute to atherosclerotic lesion 
expansion and destabilization, as lesion size was 
reduced in apoE/MMP-12double knockout mice 
compared to controls. Given the size of the MMP 
family, their overlapping substrates and numerous 
inhibitors, it is challenging to clarify the role of 
individual MMPs in the disease process.
Critical issues in the analysis
of MMPs
The critical issues when developing analytical tools 
for biomarker analysis include sample integrity, and 
dealing with different dimensions of complexity 
(i.e. complexity determined by the tissue origin, 
complexity due to the number of biomarkers that 
are being monitored to determine the progression 
of disease). It is especially important to take note of 
the methods and conditions under which the sample 
is collected. As shown in Table 2, there was a large 
variability in the MMP concentrations reported in 
the literature. Most of the researchers took 
samples either from blood plasma or serum. Some 
recommended heparin plasma to study MMPs (Jung 
et al. 1996; Yamanaka et al. 2000; Jung et al. 2001; 
Mannello, 2003; Meisser et al. 2005) because clot 
activator appears to release MMPs from cells. 
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Table 2. Concentrations of MMPs in selected human pathologies.
MMP Disease Concentration References
Human serum Other body fl uids
or tissues
MMP-1 Rheumatoid 
Arthritis
25.6 (21.9) ng/mL (Synovial fl uid) mean 
2361 (SD 2628) ng/mL
Maeda et al. 1995
MMP-1 Rheumatoid 
Arthritis
6–10 ng/mL Brennan et al. 1997
MMP-3 Rheumatoid 
Arthritis
50–100 ng/mL Brennan et al. 1997
MMP-3 Rheumatoid 
Arthritis
Healthy men: 64.5 +/− 
29.4 ng/mL; Healthy women: 
29.0 +/− 29.4 ng/mL; Early 
RA: 246.4 +/− 267.7 ng/mL; 
late RA: 224.6 +/− 237.3 ng/mL
Yamanaka et al. 2001
MMP-9 Coronary
Atherosclerosis
Control: 32.2 +/− 16.1 ng/mL
(p = 0.007) 3-vessel CAD: 
57.3 +/− 39.1 ng/mL
(p = 0.011) 1- or 2-vessel 
CAD: 40.4 +/− 25.1 ng/mL
(p = 0.044)
Kalela et al. 2002
MMP-9 Acute myocardial 
infarction 
Control: 27 +/− 8 ng/mL
Acute MI: 87 +/− 26 ng/mL
Kai et al. 1998
MMP-9 Acute myocardial 
infarction
Control: 22 +/- 6 ng/mL 
Monocytes: 192 +/− 
40 ng/mL
Zhao et al. 2005
MMP-2 Hepatitis (proenzyme)
Healthy: 752 +/− 152 ug/L
CAH: 649 +/− 168 ug/L
Lichtinghagen et al. 2000
MMP-9 Hepatitis C Healthy: 455 +/− 185 ug/L; 
CAH MMP9: 293 +/−
226 ug/L; 
Lichtinghagen et al. 2000
MMP-1 Acute viral 
hepatitis 
Healthy: 121.8 +/− 18.3 ng/mL; 
Hepatitis: 75.8 +/−
11.8 ng/mL; 
Koulentaki et al. 2002
MMP-2a Acute viral 
hepatitis 
Healthy: 1555 +/− 133 ng/mL;
Hepatitis: 789.6 +/− 68 ng/mL
Koulentaki et al. 2002
MMP-2b Acute viral 
hepatitis 
Healthy: 425 +/− 14 ng/mL,
Hepatitis: 261 +/− 14 ng/mL
Koulentaki et al. 2002
MMP-3 Acute viral 
hepatitis 
Healthy: 21.2 +/− 5.2 ng/mL;
Hepatitis: 5.2 +/− 3.4 ng/mL
Koulentaki et al. 2002
MMP-9a Acute viral 
hepatitis 
Healthy: 65.1 +/− 9.4 ng/mL;
Hepatitis: 33.9 +/− 6.9 ng/mL
Koulentaki et al. 2002
MMP-9b Acute viral 
hepatitis 
Healthy:5.8+/− 0.34 ng/mL;
Hepatitis: 2.7 +/− 0.16 ng/mL
Koulentaki et al. 2002
MMP-1 Osteoarthritis
of the hip
Healthy: 2.2–22.9 ng/mL;
OA: range 23.5-1850,
mean 351 +/− 538 ng/mL; 
Masuhara et al. 2002
MMP-2 Osteoarthritis
of the hip
Healthy: 367–770 ng/mL;
OA: range 63-1670, mean 
562.92 +/− 442.53 ng/mL
Masuhara et al. 2002
MMP-3 Osteoarthritis
of the hip
Healthy: 15–72 ng/mL;
OA: range 12.5-636,
mean 114+/− 176 ng/mL
Masuhara et al. 2002
(Continued)
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Others have found that buffered citrate is the 
anticoagulant of choice because it slows down the 
release of MMPs by blood cells, and thus is not as 
dependent upon time as other anticoagulants 
(Coussens et al. 2002; Snoek-van Beurden, 2005; 
Thrailkill et al. 2005). The effect of blood collection 
methods on the concentration of MMPs was 
investigated by Manello who reported 2- to 10-fold 
higher concentrations of MMP-9 in serum than in 
heparin- and EDTA-plasma, and found that plastic 
tubes with a silica gel coated surface, as clot 
activator, gave even a 2-fold higher concentrations 
for serum samples (Manello, 2003). Nonetheless, 
he recommended heparin-plasma because platelet 
activation and neutrophil mobilization during 
clotting could produce such differences. Furthermore, 
he hypothesized that some of the disparity resulted 
from different storage temperatures when the blood 
was allowed to clot and the time at which the 
samples were centrifuged (Mannello et al. 2003). 
Regarding the storage temperature of human 
samples, it was reported that after 2 years storage at 
−80°C the MMP-9 concentration in citrate-plasma 
dropped by 65%, and it was estimated that only 1% 
would remain after 43 months (Rouy et al. 2005). 
In summary, the concentration of MMPs detected 
depends greatly on pre-analytical conditions of the 
blood samples, so great care should be exercised in 
keeping conditions constant for sample preparation. 
Additionally, it is also essential to note whether it 
is desired to measure latent, active, MMP-TIMP 
complexes, or both latent and active MMPs, because 
different techniques account for different forms of 
MMP. Other analytical challenges include the fact 
that most MMPs are regulated by post-translational 
mechanisms that make it diffi cult to identify them 
with conventional genomic and proteomic tools, and 
that MMPs are inhibited by endogenous binding 
proteins such as TIMPs.
Multiplexed profi ling of MMPs 
in biological samples
Although MMP gene profi ling conducted to date 
is most extensive for cancer, several studies have 
identified genetic variants associated with 
cardiovascular disease (Ye, 2006). Flex et al. 
(2007) found that MMP-1 and MMP-3 gene poly-
morphisms were significantly associated with 
peripheral arterial occlusive disease (Flex et al. 
2007), and a specifi c MMP-3 polymorphism was 
strongly associated with acute myocardial infarc-
tion (Abilleira et al. 2006). While MMP genotype 
profi ling may not be the best indicator of disease 
state, it is possible that polymorphism analysis can 
help identify patients at high risk or those who are 
more likely to respond to various therapeutics.
A much better indication of current disease state 
may be ascertained through detection of specifi c 
molecules and protein expression profi les of patient 
samples. However, these data are typically obtained 
by enzyme immunoassays and mass spectrometry, 
Table 2. (Continued).
MMP Disease Concentration References
Human serum Other body fl uids
or tissues
MMP-9 Osteoarthritis
of the hip
Healthy: 12–71 ng/mL;
OA: range 3.1-30.5,
mean 11.05 +/− 9.42 ng/mL
Masuhara et al. 2002
MMP-9 Gastric cancer (Plasma)
Healthy: 36 +/−
13 ng/mL;
Cancer: 81 +/−
53 ng/mL
Torii et al. 1997
MMP-2 Ovarian cancer Kim et al. 2006
Duffy et al. 2000
Yoon et al. 2003
Folgueras et al. 2004
Stuelten et al. 2005
Jinga et al. 2006
MMP-3 Breast cancer
ameasurement by ELISA
bmesurement by zymography
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respectively, which are very tedious processes, 
despite the latest developments in both technolo-
gies. The feasibility of using these methods to 
monitor MMPs as biomarkers is further compli-
cated by the requirement for specifi c antibodies- 
one for capture and one for detection in enzyme 
immunoassays, and mass spectrometry is not sen-
sitive enough to detect individual proteins that span 
over fourteen orders of magnitude in concentration 
in the human serum or plasma. Furthermore, car-
diovascular disease likely results when multiple 
molecules or systems have gone awry, thus such 
analytical tools that can provide that information 
reliably and fast would need to be developed.
Currently, analytical methods for the determina-
tion of MMPs in biological samples include ELISA 
(enzyme-linked immunosorbent assays, including 
multiplexed ELISAs in the form of antibody 
arrays); zymography; optical methods such as 
near-IR (infrared) optical imaging, fl uorescence, 
and surface plasmon resonance spectroscopy; the 
use of active-site probes followed by enzymatic 
digestion of the captured MMPs, and LC-MS/MS 
(liquid chromatography-mass spectroscopy) 
analysis of the digested MMPs.
Enzyme immunoassays
Of the currently available methods for MMP detec-
tion, there are several commercially available 
ELISA kits (e.g. Biotrack, Fluorokine Multianalyte 
Profi ling and Quantikine HS from R&D Systems), 
as well as a Luminex assay (Thrailkill et al. 2005), 
but these assays yield imprecise and potentially 
misleading results because they cannot distinguish 
between the active and latent forms of the enzyme 
or between specific MMPs and their TIMP 
complexes (Zucker et al. 1994; Maeda et al. 1995; 
Brennan et al. 1997; Torii et al. 1997; Yamanaka 
et al. 2000; Koulentaki et al. 2002; Masuhara et al. 
2002; Dandona et al. 2003; Watanabe et al. 2005, 
Nilsson et al. 2006). Sandwich ELISAs do have 
greater sensitivity, but they require two different 
antibodies for each individual MMP, and a separate 
assay plate must be used for the measurement of 
each MMP, making for a very time consuming 
assay. The detection limits for Quantikine HS from 
R&D Systems (Nilsson et al. 2006) vary greatly 
for each MMP (i.e. MMP-2 is 0.37 ng/mL; MMP-3 
is 2.35 ng/mL and MMP-7 is 0.09 ng/mL). Multi-
plexed ELISAs have been reported, but these tend 
to exhibit high cross-reactivity among various 
MMPs because these proteins share common 
domains. A 10 × 10 bead matrix (Luminex 
Corporation) in which each bead contains a specifi c 
proportion of a red/orange fl uorescent dye was 
reported for analysis of MMP-1, -2, -3, -8, and -9 
in plasma (Thrailkill et al. 2005). This assay 
allowed for simultaneous determination of each of 
these MMPs, thus eliminating any possible opera-
tor error in sampling and also reducing sample 
volume to only 10 µL for all fi ve analytes. When 
compared to single analyte ELISA, this represented 
a fi ve-fold reduction in sample volume and makes 
the assay more amenable to pediatric population 
(Thrailkill et al. 2005).
A prototype antibody array (Agilent Technolo-
gies) consisting of forty capture monoclonal 
antibodies to human serum proteins, including 
MMPs, TIMPs, and MMP-TIMP complexes was 
used to assess the differential protein levels 
between control (7 healthy subjects chosen ran-
domly) and patient (11 subjects with a history of 
cardiovascular disease) plasma samples taken one 
hour after the treadmill experiment. Based on the 
resulting data (Fig. 2), proteins were then arranged 
in descending order starting with those having 
higher average levels in the patient group com-
pared to control (above the red horizontal line in 
the heatmap). Proteins with relatively high average 
levels in both the control and patient group were 
placed near the bottom of this listing. Finally, 
proteins for which the control group had higher 
average levels than the patient group were ranked 
at the very bottom (below the red line). In each 
group, the proteins were further ordered by Gauss-
ian error score so that the proteins with the most 
different distributions of protein levels between 
the two sample group are on the top. In the 
heatmap (Fig. 2A), each row represents color-coded 
protein levels for each of the thirty three target 
proteins, and each column represents all protein 
levels for one sample. Blue indicates the lowest 
protein level in a given row, and yellow indicates 
the highest level. Plots in Figure 2B show actual 
distributions of specifi c protein levels among the 
two groups for three proteins with most dramatic 
difference between the two groups. Below the 
plots, green x’s show protein levels in control 
group, red x’s show protein levels in Treadmill 
patient groups. Green and red graphs show cor-
responding normal fi ts. Among the most differen-
tiating proteins are MMP-2/TIMP-2 complex, 
MMP-10, MMP-9, TIMP-1 and TIMP-2. Classi-
fi cation analysis using leave one out cross-validation 
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algorithm showed that one can predict normal 
or disease status of the sample based on protein 
levels of top fi ve proteins mentioned above. The 
data generated with this prototype array is 
unique because this allows simultaneous deter-
mination of thirty nine analytes, including sev-
eral MMPs and MMP-TIMP complexes, requires 
only 10 µL sample volume, and the amount of 
antibody present on each feature of the array is 
35 pg. This was possible because the arrays were 
printed using an inkjet deposition tool that 
delivers 35 pL on each spot with a deviation of 
only 1–2 µm for a spot of 50 µm in diameter. 
Although 60 monoclonal antibodies were 
deposited onto the array, the multiplexed assay 
targeted only thirty nine analytes because only 
thirty nine detection antibodies were working 
properly in the assay.
A B 
C901
Controls Treadmill
Figure 2. Multiplex analysis of MMP levels in patient samples. Plasma samples collected from subjects from a treadmill study (7 "Controls" 
and 11 "Treadmill" subjects) were analyzed using a prototype antibody array (Agilent Technologies). A). Heatmap analysis ranking proteins 
found in the highest concentrations among test subjects compared to control protein levels. Yellow indicated the highest protein levels, blue 
the lowest. For each patient (11 patients with a history of cardiovascular disease) and control sample (7 healthy subjects chosen randomly), 
the data shown represents the average of 4 measurements. B) In the Gaussian plots on the right, green shows the individual protein con-
centrations for control subjects, and red indicates protein levels for patients subjected to the treadmill, with overlap indicated in blue. Values 
for MMP-10 (top), MMP-2/TIMP-2 complex (middle) and TIMP-1 (bottom) are shown. The antibody array contained 720 features (the 60 
monoclonal antibodies and positive and negative controls were printed at two concentrations in quadruplicate) and there were eight identi-
cal arrays on the each 1x3 in modifi ed glass slide. Thirty nine polyclonal antibodies were used as detection antibodies in the assay, and the 
fi nal step in the detection was accomplished with Cy3-streptavidin.
84
Lopez-Avila and Spencer
Clinical Medicine: Cardiology 2008:2 
Zymography
This method is also widely used and identifi es 
MMPs by the degradation of their preferential 
substrate and by their molecular weight (Snoek-van 
Beurden, 2005). All types of zymography are 
similar to gelatin zymography, the substrate simply 
differs depending on the MMP being analyzed. In 
zymography, the proteins are separated by electro-
phoresis under denaturing (in the presence of SDS) 
and in nonreducing conditions; the separation is 
done in a polyacrylamide gel that contains the 
specifi c substrate. After electrophoresis, the gel is 
washed to remove SDS, following which the 
MMPs partially renature and recover their activity. 
The gel is then stained blue, and the MMPs are 
visible as clear bands against the blue substrate in 
the background and can be measured by densitom-
etry (Snoek-van Beurden, 2005). Proenzymes and 
active forms of MMPs can be distinguished by 
molecular weight. An added benefi t of this method 
is that it also results in separation of MMP-TIMP 
complexes (Snoek-van Beurden, 2005). Gelatin 
zymography is extremely sensitive for gelatinases 
like MMP-2 and MMP-9 (i.e. 10 pg of MMP-2 can 
be easily detected) while casein zymography is 
more suitable for stromelysins MMP-1, -7, -11, 
-12, and -13. Collagen zymography is also used 
for detection of MMP-1, -2, -9, and -13. In situ 
zymography, which can detect only active MMPs, 
allows the localization of MMPs in tissue sections 
and uses a substrate that is deposited on or under 
a frozen section of an unfi xed tissue sample. In 
these assays it is important to use control slides 
with appropriate MMP inhibitors, to discriminate 
between the different classes of MMPs (Snoek-van 
Beurden, 2005).
Optical methods
Near-IR optical imaging has been used primarily 
for detection of MMPs in tumor tissue (Bremer 
et al. 2001). An optical contrast agent was devel-
oped that was highly activatable by MMP-2–
induced conversion. Signal characteristics of the 
probe were measured ex vivo with a recombinant 
enzyme. Animal tumor models were established 
with MMP-2–positive (human fi brosarcoma cell 
line, n = 4) and MMP-2–negative (well-differenti-
ated mammary adenocarcinoma, n = 4) tumor cell 
lines. Both tumors were implanted into nude mice 
and were optically imaged after intravenous admin-
istration of the MMP-2–sensitive probe (Bremer 
et al. 2001).
Another optical method, which measures only the 
MMPs activity and has been used to evaluate MMP 
inhibitors, is a collagenase assay using capillary gel 
electrophoresis (CGE) and laser-induced fl uores-
cence detection or LIF (Sano et al. 2004). This col-
lagenase assay employs dynamic fl uorescent labeling 
with NanoOrange dye, and measures fragments of 
type I and II collagen, which are produced from the 
native collagen by cleavage with a particular MMP. 
The CGE-LIF with a capillary array system is ideal 
as a high throughput system. An assay for detection 
of both the proform and the active form of MMP-2 
with a surface plasmon resonance (SPR) spectrom-
eter, was reported by Pieper-Furst et al. 2004. This 
assay involves mixing of the MMP-2 with anti-
MMP-2 antibody adsorbed to colloidal gold and 
injection into the fl owcell of the SPR where TIMP-2 
is immobilized. TIMP-2 has at least two binding sites 
for MMP-2; when the antibody binds the MMP-2 
fi rst, one site in MMP-2 is occupied by the antibody, 
leaving a second site for TIMP. The detection limit 
for the SPR assay corresponds to 36 pg/mL and takes 
only 30 min including the regeneration of the sensor 
(Pieper-Furst et al. 2004). The SPR assay is not 
applicable to the detection of the MMP-TIMP com-
plex since TIMP is one of the ligands.
Mass spectrometry
Identifi cation of MMPs and other metalloprote-
ases with a set of alkyne-tagged hydroxamate-
benzophenone (HxBPyne) probes was reported 
recently (Sieber et al. 2006), and it involves enzy-
matic digestion after capture of the MMPs using 
biotin-azide tags and avidin chromatography fol-
lowed by analysis of the MMP-digests by LC-MS/
MS. The LC-MS/MS method is very lengthy, and 
it is still not fully reliable when it comes to identify-
ing proteins in the digested form, because the iden-
tifi cation often relies on the presence of only a few 
peptides from the digested protein. Nonetheless, 
analysis of cell and tissue proteomes treated with 
an optimal set of probes (i.e. HxBPyne probes) 
resulted in the identifi cation of more than twenty 
different metalloproteases (i.e. MMP-1, MMP-3, 
MMP-7, MMP-12 at detection limits of 0.5, 2.5, 
0.25, and 1 µg/mL of proteome, respectively).
Is there a need for new tools
to profi le MMPs?
Although TIMP-1 and TIMP-2 were considered 
initially as good inhibitors of MMPs in cancer 
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progression, it turned out that small molecule 
inhibitors containing both hydroxamate and non-
hydroxamate binding sites were more attractive 
and five different inhibitors (i.e. Marimastat, 
Prinomastat, Tanomastat, BMS 275291, and Neo-
vastat) made it into advanced stages of the clinical 
development with disappointing results. The rapid-
ity with which these inhibitors moved into clinical 
trials raised a very important question: “Do any 
MMPs play an important role in advanced lung 
and pancreatic cancer, and if so, which ones?” 
(Coussens et al. 2002). Because there is no ana-
lytical tool that can answer this question for all 
twenty-four MMPs measured at the same time, 
what is really needed is a better tool for multiplexed 
profi ling of this important class of proteins. The 
data included here for the prototype antibody array 
demonstrate that MMPs can be reliably measured 
at ng/mL concentrations in human serum, but this 
array is not yet available commercially and the 
authors are not aware of any commercial multi-
plexed ELISA kits that can measure all twenty-four 
MMPs simultaneously.
One potentially very promising analytical 
method for profi ling all MMPs in a sample under 
development in the author’s laboratory uses two 
separation steps: immunoaffi nity chromatography 
using an anti-MMP catalytic domain antibody to 
“fi sh out” the MMPs from the tissue (i.e. human 
serum or plasma) and high- pressure liquid 
chromatography (HPLC) to separate the MMPs 
as individual proteins (see Fig. 3). These separa-
tions are followed by a detection step in which the 
metal ion (i.e. zinc at mass-to-charge of 66 amu 
identifi ed here as 66Zn) is measured by inductively-
coupled plasma mass spectrometry (ICPMS). The 
66Zn scan is specifi c only to MMPs because they 
are isolated from the sample (i.e. human serum) 
by immunoaffi nity chromatography with an anti-
MMP antibody. This technique is very powerful 
in the sense that it can profi le all MMPs in one 
single analysis that can be accomplished in thirty 
minutes or less. In addition, it is both very 
sensitive and selective (i.e. compare the UV scan 
and the ICPMS scans in Figure 3) because it will 
focus specifi cally on the metal ion that is at the 
heart of the protein functionality. For details on 
the use of HPLC-ICPMS for the identifi cation of 
metalloproteins, the reader may refer to a paper 
on determination of ceruloplasmin (Cp), a copper 
protein, in human serum published by Lopez-
Avila et al. 2006 in which the identifi cation of Cp 
is based on the retention time match of the 
unknown in the serum sample with the Cp exter-
nal standard and the presence of 63Cu and 65Cu at 
a ratio of 2.2 ± 0.1.
Multiplexed analysis of MMPs in biological 
samples by immunoaffinity chromatography 
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Figure 3. Schematic diagram of the HPLC-ICPMS approach for the determination of MMPs following capture on an immunoaffi nity 
column. The UV scan at 215 nm shows the presence of a large number of proteins in the human serum. The ICPMS scans for 63Cu and 
66Zn show the selectivity of the ICPMS technique in detecting only the metalloprotein(s). The 63Cu peak at scan 500 corresponds to Cp, and 
the Zn peak at scan 730 has not been identifi ed yet. The human serum sample shown here has not been processed through an immunoaf-
fi nity column, therefore the Zn scan is not indicative of the presence of MMPs. It is only shown here to demonstrate the selectivity of the 
ICPMS technique for metalloproteins.
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followed by HPLC-ICPMS is a new concept and 
has not been reported in the literature for this class 
of proteins. In this case, MMPs are identifi ed by 
retention time match with specifi c MMP standards 
and by the zinc scan, which is done using the ICPMS 
system. Because MMPs are “fi shed-out” from the 
sample with a reagent that is quite specifi c for MMPs 
(i.e. antibodies that recognize the catalytic domain, 
which is common in all MMPs), this method will 
generate an MMP fi ngerprint that can help identify 
the disease, track disease progression, and help 
evaluate how therapeutic agents can alter the MMP 
fi ngerprint. An MMP fi ngerprint analyzing levels of 
all MMPs is crucial, especially because it has been 
reported that MMP-7, -8, -9, and -13 can be inacti-
vated by MMP-3 (Samnegard et al. 2006).
There are diffi culties in implementing such 
approach because many of the MMPs are not avail-
able commercially as intact proteins but as recom-
binant fragments, and they will need to be 
expressed and purifi ed for such developmental 
work to be accomplished.
Summary
MMPs are an important class of enzymes that play 
roles in both normal physiology and several disease 
states. Efforts to clarify the importance of particu-
lar MMPs in specifi c pathologies have been ham-
pered by the complex biology of this large family 
of related enzymes and their TIMP binding part-
ners. In addition, accurate quantitation of multiple 
of MMPs in patient samples is confounded by 
limitations of the currently available detection 
methods. With the further development and com-
mercialization of the HPLC-ICPMS technique, it 
seems likely that multiple MMPs levels will be 
able to be more easily monitored and correlated 
with various aspects of human disease.
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